The treatment approach for HR+/HER2- advanced breast cancer has grown increasingly complex, with multiple targeted options now available.1,2 Navigating this evolving landscape requires a strategic approach to sequencing that balances tumor biology, treatment history, and individual patient factors.
Early biomarker testing for actionable mutations, including PIK3CA, AKT1, PTEN, and ESR1, provides the foundation for treatment planning.1,2 Understanding alteration status at diagnosis and progression enables clinicians to map potential therapeutic pathways before they become immediately necessary, ensuring informed decision-making when treatment changes are required.
Several key considerations guide sequencing decisions. The response to prior CDK4/6 inhibitor plus endocrine therapy informs expectations for subsequent lines of treatment.1,2 Patient fitness and comorbidities influence tolerability of various regimens and their associated adverse event profiles. Importantly, treatment selection at each decision point should preserve future options, maintaining therapeutic flexibility as disease evolves.
For patients with PIK3CA mutations, options include PI3K inhibitors in combination with endocrine therapy. One such agent combines with fulvestrant and palbociclib in the first-line setting, representing a triple-combination approach.3 AKT inhibitors demonstrate activity across PIK3CA, AKT1, and PTEN alterations when combined with fulvestrant, offering broader applicability across pathway alterations.4
Clinical evidence supports flexible integration of pathway inhibitors at appropriate treatment points based on alteration status and prior therapy exposure. Rather than rigid algorithms, treatment sequencing should reflect individualized assessment incorporating molecular drivers, treatment goals, and patient preferences.3,5
Shared decision-making proves essential in this complex landscape.5 Transparent discussions about treatment expectations, potential benefits, and anticipated adverse events align medical recommendations with patient priorities, creating treatment plans that address both disease control and quality-of-life considerations throughout the cancer journey.
Take our metastatic breast cancer quiz to see how your knowledge compares to your peers.
